RDY introduces Levocetirizine tablets in the U.S. market

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Mar 28 2011Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories (NYSE:RDY) has launched Levocetirizine tablets (5mg), a bioequivalent generic version of Xyzal® tablets in the US market. The United States Food & Drug Administration (USFDA) approved Dr. Reddy's ANDA for Levocetirizine tablets on February 24, 2011.

Levocetirizine had total U.S. sales of approximately $238 million for the twelve months ending September 30, 2010 according to IMS Health. Dr. Reddy's Levocetirizine tablets are available in 90 count bottles.

Source:

Dr. Reddy's Laboratories Ltd.

Posted in: Pharmaceutical News

Tags: , ,

Comments (0)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback